The FDA approved trifluridine and tipiracil with bevacizumab for patients with previously treated metastatic colorectal cancer.
The approval applies to use of the combination by patients who received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy and — if RAS wild-type — an anti-EGFR therapy.